| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ascorbyl palmitate is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C. Ascorbyl palmitate is a highly bioavailable, fat-soluble form of ascorbic acid (vitamin C) and possesses all the properties of native water-soluble counterpart, that is vitamin C. Ascorbyl Palmitate — Ascorbyl palmitate (AP; also called L-ascorbyl palmitate, vitamin C palmitate) is the 6-O-palmitate ester of L-ascorbic acid, used primarily as a lipid-phase antioxidant/preservative (food additive E304(i), INS 304(i)) and in topical/cosmetic formulations. It is an amphipathic, fat-soluble vitamin C derivative that localizes to lipid interfaces and can be enzymatically hydrolyzed to ascorbic acid + palmitate (extent and site depend on formulation and biology). In the Nestronics index (pid 35), AP is linked to limited cancer-pathway annotations largely derived from a small nanoformulation literature rather than broad clinical oncology deployment. Primary mechanisms (ranked):
Bioavailability / PK relevance: As a fatty acid ester, AP partitions into dietary and biological lipids; oral exposure is formulation-dependent and it is generally believed to undergo esterase-mediated hydrolysis to ascorbic acid plus palmitate. Human oncology-relevant systemic PK for intact AP is not well standardized in the open literature; most “therapeutic” claims rely on delivery systems (e.g., solid lipid nanoparticles) rather than conventional oral supplement dosing. In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar-to-millimolar in-vitro concentrations and/or nano-enabled delivery that can exceed typical systemic levels achievable from food-additive exposure; translation hinges on formulation, local delivery, and tumor targeting rather than simple oral dosing. Clinical evidence status: Predominantly preclinical (in vitro/in vivo) and largely formulation-driven (nano/SLN platforms). No established role as an anticancer drug in routine clinical oncology; clinical use is mainly as an antioxidant excipient/food additive. Ascorbyl Palmitate — Mechanistic Pathway Matrix (Cancer Context)
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells. The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment. Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS). – In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer. • Expression Patterns in Tumors: – Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment. – Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation. |
| 1146- | AsP, | Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms |
| - | in-vivo, | Nor, | NA |
| 5384- | AsP, | MEL, | Synergistic Anticancer Effect of Melatonin and Ascorbyl Palmitate Nanoformulation: A Promising Combination for Cancer Therapy |
| - | in-vivo, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:35 Target#:563 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid